Header Logo

Connection

BANU K ARUN to Middle Aged

Back to Details
This is a "connection" page, showing publications BANU K ARUN has written about Middle Aged.
BANU K ARUN
Connection Strength
1.233
Middle Aged
  1. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open. 2024 Jun 03; 7(6):e2418486.
    View in: PubMed
    Score: 0.035
  2. Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer. 2021 09; 154:35-45.
    View in: PubMed
    Score: 0.029
  3. Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila). 2020 09; 13(9):795-802.
    View in: PubMed
    Score: 0.027
  4. Multigene panel testing results in patients with multiple breast cancer primaries. Breast J. 2020 07; 26(7):1337-1342.
    View in: PubMed
    Score: 0.026
  5. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.025
  6. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
    View in: PubMed
    Score: 0.024
  7. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726.
    View in: PubMed
    Score: 0.023
  8. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2018 05; 16(5):518-524.
    View in: PubMed
    Score: 0.023
  9. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
    View in: PubMed
    Score: 0.023
  10. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018 02 06; 18(1):152.
    View in: PubMed
    Score: 0.023
  11. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306.
    View in: PubMed
    Score: 0.023
  12. BRCA mutations in women with inflammatory breast cancer. Cancer. 2018 02 01; 124(3):466-474.
    View in: PubMed
    Score: 0.022
  13. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med. 2017 Nov; 6(11):2515-2522.
    View in: PubMed
    Score: 0.022
  14. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma. Clin Oncol (R Coll Radiol). 2017 Jun; 29(6):335-343.
    View in: PubMed
    Score: 0.021
  15. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther. 2017 03; 16(1):3-20.
    View in: PubMed
    Score: 0.021
  16. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77.
    View in: PubMed
    Score: 0.020
  17. Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. J Health Care Poor Underserved. 2015 Aug; 26(3):784-91.
    View in: PubMed
    Score: 0.019
  18. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.
    View in: PubMed
    Score: 0.017
  19. Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients. Breast J. 2013 Jul-Aug; 19(4):431-4.
    View in: PubMed
    Score: 0.016
  20. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7.
    View in: PubMed
    Score: 0.016
  21. Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.
    View in: PubMed
    Score: 0.016
  22. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012 May; 133(1):347-55.
    View in: PubMed
    Score: 0.015
  23. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82.
    View in: PubMed
    Score: 0.015
  24. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
    View in: PubMed
    Score: 0.015
  25. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5.
    View in: PubMed
    Score: 0.015
  26. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
    View in: PubMed
    Score: 0.014
  27. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.
    View in: PubMed
    Score: 0.014
  28. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.
    View in: PubMed
    Score: 0.014
  29. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
    View in: PubMed
    Score: 0.014
  30. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01; 117(17):3900-7.
    View in: PubMed
    Score: 0.014
  31. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2.
    View in: PubMed
    Score: 0.014
  32. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4214-20.
    View in: PubMed
    Score: 0.013
  33. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010 Jun; 28(5):554-9.
    View in: PubMed
    Score: 0.013
  34. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
    View in: PubMed
    Score: 0.012
  35. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
    View in: PubMed
    Score: 0.012
  36. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
    View in: PubMed
    Score: 0.012
  37. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008 Jan-Feb; 14(1):62-8.
    View in: PubMed
    Score: 0.011
  38. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008 Oct; 111(3):405-10.
    View in: PubMed
    Score: 0.011
  39. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
    View in: PubMed
    Score: 0.011
  40. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 Aug 15; 13(16):4943-8.
    View in: PubMed
    Score: 0.011
  41. Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol. 2006 May; 19(5):622-9.
    View in: PubMed
    Score: 0.010
  42. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1681-5.
    View in: PubMed
    Score: 0.009
  43. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.009
  44. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904). BMC Med Inform Decis Mak. 2024 Sep 27; 24(1):272.
    View in: PubMed
    Score: 0.009
  45. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
    View in: PubMed
    Score: 0.009
  46. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr. 2024 Jul 01; 8(4).
    View in: PubMed
    Score: 0.009
  47. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
    View in: PubMed
    Score: 0.009
  48. Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials. 2024 Jul; 142:107564.
    View in: PubMed
    Score: 0.009
  49. Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024 Jun 20; 42(18):2186-2195.
    View in: PubMed
    Score: 0.009
  50. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer. 2003 Dec 15; 98(12):2554-9.
    View in: PubMed
    Score: 0.008
  51. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
    View in: PubMed
    Score: 0.008
  52. Progress in breast cancer chemoprevention. Endocr Relat Cancer. 2002 Mar; 9(1):15-32.
    View in: PubMed
    Score: 0.007
  53. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
    View in: PubMed
    Score: 0.007
  54. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.007
  55. Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest. 2001; 19(8):779-82.
    View in: PubMed
    Score: 0.007
  56. Patient characteristics associated with sleep disturbance in breast cancer survivors. Support Care Cancer. 2021 May; 29(5):2601-2611.
    View in: PubMed
    Score: 0.007
  57. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 10; 21(10):1269-1282.
    View in: PubMed
    Score: 0.007
  58. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. Ann Surg Oncol. 2020 Nov; 27(12):4613-4621.
    View in: PubMed
    Score: 0.007
  59. Should abbreviated breast MRI be compliant with American College of Radiology requirements for MRI accreditation? Magn Reson Imaging. 2020 10; 72:87-94.
    View in: PubMed
    Score: 0.007
  60. Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. Support Care Cancer. 2020 Dec; 28(12):5821-5832.
    View in: PubMed
    Score: 0.007
  61. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 05 10; 38(14):1539-1548.
    View in: PubMed
    Score: 0.007
  62. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am. 2000 Jan-Feb; 6(1):21-4.
    View in: PubMed
    Score: 0.006
  63. Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study. Clin Oncol (R Coll Radiol). 2020 02; 32(2):e67-e75.
    View in: PubMed
    Score: 0.006
  64. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer. Clin Oncol (R Coll Radiol). 2020 02; 32(2):e39-e45.
    View in: PubMed
    Score: 0.006
  65. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 12; 76(6):831-842.
    View in: PubMed
    Score: 0.006
  66. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.006
  67. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila). 2019 07; 12(7):481-490.
    View in: PubMed
    Score: 0.006
  68. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999 Jan 01; 85(1):93-9.
    View in: PubMed
    Score: 0.006
  69. Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer. Br J Radiol. 2019 Mar; 92(1095):20180928.
    View in: PubMed
    Score: 0.006
  70. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 11 01; 36(31):3134-3143.
    View in: PubMed
    Score: 0.006
  71. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.006
  72. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer. J Glob Oncol. 2018 08; 4:1-9.
    View in: PubMed
    Score: 0.006
  73. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. Indian J Cancer. 2018 Apr-Jun; 55(2):125-133.
    View in: PubMed
    Score: 0.006
  74. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.006
  75. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):415-423.
    View in: PubMed
    Score: 0.006
  76. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018 Jan 01; 124(1):36-45.
    View in: PubMed
    Score: 0.006
  77. Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw. 2017 06; 15(6):797-803.
    View in: PubMed
    Score: 0.005
  78. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
    View in: PubMed
    Score: 0.005
  79. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer. 2017 07; 25(7):2103-2109.
    View in: PubMed
    Score: 0.005
  80. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
    View in: PubMed
    Score: 0.005
  81. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist. 2016 07; 21(7):869-74.
    View in: PubMed
    Score: 0.005
  82. Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer. 2016 09; 24(9):3775-82.
    View in: PubMed
    Score: 0.005
  83. Examining Mediators and Moderators of Yoga for Women With Breast Cancer Undergoing Radiotherapy. Integr Cancer Ther. 2016 09; 15(3):250-62.
    View in: PubMed
    Score: 0.005
  84. A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat. 2016 Jan; 155(2):375-83.
    View in: PubMed
    Score: 0.005
  85. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73.
    View in: PubMed
    Score: 0.005
  86. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
    View in: PubMed
    Score: 0.005
  87. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
    View in: PubMed
    Score: 0.005
  88. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.005
  89. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.005
  90. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.
    View in: PubMed
    Score: 0.004
  91. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist. 2014 Aug; 19(8):797-804.
    View in: PubMed
    Score: 0.004
  92. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer. 2014 Jun; 13(2):291-9.
    View in: PubMed
    Score: 0.004
  93. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology. 2014 Nov; 23(11):1220-8.
    View in: PubMed
    Score: 0.004
  94. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.004
  95. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun; 28(3):272-82.
    View in: PubMed
    Score: 0.004
  96. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014 Apr 01; 32(10):1058-65.
    View in: PubMed
    Score: 0.004
  97. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64.
    View in: PubMed
    Score: 0.004
  98. Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged = 55 years. Mol Carcinog. 2015 Apr; 54(4):281-90.
    View in: PubMed
    Score: 0.004
  99. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013 Oct; 22(10):2354-63.
    View in: PubMed
    Score: 0.004
  100. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500.
    View in: PubMed
    Score: 0.004
  101. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.004
  102. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
    View in: PubMed
    Score: 0.004
  103. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8.
    View in: PubMed
    Score: 0.004
  104. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54.
    View in: PubMed
    Score: 0.004
  105. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
    View in: PubMed
    Score: 0.004
  106. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.004
  107. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat. 2012 Apr; 132(3):1147-55.
    View in: PubMed
    Score: 0.004
  108. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila). 2011 Nov; 4(11):1852-62.
    View in: PubMed
    Score: 0.004
  109. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8.
    View in: PubMed
    Score: 0.004
  110. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
    View in: PubMed
    Score: 0.003
  111. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.003
  112. External qigong therapy for women with breast cancer prior to surgery. Integr Cancer Ther. 2010 Dec; 9(4):348-53.
    View in: PubMed
    Score: 0.003
  113. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010 Sep 01; 28(25):3917-21.
    View in: PubMed
    Score: 0.003
  114. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.003
  115. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):235-44.
    View in: PubMed
    Score: 0.003
  116. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51.
    View in: PubMed
    Score: 0.003
  117. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8.
    View in: PubMed
    Score: 0.003
  118. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 2010 Jul; 122(1):243-9.
    View in: PubMed
    Score: 0.003
  119. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol. 2009 Sep; 46(15):3037-49.
    View in: PubMed
    Score: 0.003
  120. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48.
    View in: PubMed
    Score: 0.003
  121. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
    View in: PubMed
    Score: 0.003
  122. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
    View in: PubMed
    Score: 0.003
  123. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
    View in: PubMed
    Score: 0.003
  124. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 2008 Jul 08; 99(1):68-71.
    View in: PubMed
    Score: 0.003
  125. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008 Oct; 19(10):1713-9.
    View in: PubMed
    Score: 0.003
  126. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008 Apr 14; 8:101.
    View in: PubMed
    Score: 0.003
  127. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 01; 112(7):1455-61.
    View in: PubMed
    Score: 0.003
  128. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008 May-Jun; 14(3):261-7.
    View in: PubMed
    Score: 0.003
  129. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
    View in: PubMed
    Score: 0.003
  130. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006 Sep 15; 107(6):1348-54.
    View in: PubMed
    Score: 0.003
  131. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Sep 01; 107(5):935-44.
    View in: PubMed
    Score: 0.003
  132. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.003
  133. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4274-82.
    View in: PubMed
    Score: 0.003
  134. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60.
    View in: PubMed
    Score: 0.002
  135. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
    View in: PubMed
    Score: 0.002
  136. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer. 2005 Sep 09; 4:33.
    View in: PubMed
    Score: 0.002
  137. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005 Aug 01; 11(15):5401-9.
    View in: PubMed
    Score: 0.002
  138. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
    View in: PubMed
    Score: 0.002
  139. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005 Jan; 89(2):149-57.
    View in: PubMed
    Score: 0.002
  140. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 2005; 26(3):271-4.
    View in: PubMed
    Score: 0.002
  141. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.002
  142. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
    View in: PubMed
    Score: 0.002
  143. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102.
    View in: PubMed
    Score: 0.002
  144. Should mammographic screening be done in primary ovarian cancer?: A case control study in Turkish women. Med Oncol. 2004; 21(2):139-43.
    View in: PubMed
    Score: 0.002
  145. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61.
    View in: PubMed
    Score: 0.002
  146. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 01; 21(17):3249-54.
    View in: PubMed
    Score: 0.002
  147. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
    View in: PubMed
    Score: 0.002
  148. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01; 20(7):1800-8.
    View in: PubMed
    Score: 0.002
  149. Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000 Feb; 17(1):29-34.
    View in: PubMed
    Score: 0.002
  150. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant. 1999 Apr; 23(7):667-73.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.